Clinical Trial Update: Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Hu14.18-Interleukin-2 fusion protein in advanced melanoma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• hu14.18-Interleukin-2 fusion protein (hu14.18-IL-2)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED